United Therapeutics. has filed a patent for an advanced manufactured transwell (AM-transwell) with a synthetic bioink-printed lower chamber, upper chamber, membrane, and legs. The patent also includes methods for making and using the AM-transwell. GlobalData’s report on United Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights United Therapeutics Corp - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on United Therapeutics, Cancer treatment biomarkers was a key innovation area identified from patents. United Therapeutics's grant share as of January 2024 was 46%. Grant share is based on the ratio of number of grants to total number of patents.

Advanced manufactured transwell with synthetic bioink for cell culture

Source: United States Patent and Trademark Office (USPTO). Credit: United Therapeutics Corp

The patent application (Publication Number: US20240034988A1) describes an advanced manufactured transwell (AM-transwell) with specific features and components. The AM-transwell includes a lower chamber, an upper chamber, a membrane between the chambers, and one or more legs forming part of the lower chamber. Importantly, the lower chamber, upper chamber, membrane, and legs are printed using a synthetic bioink, enhancing the manufacturing process and potentially improving performance.

Furthermore, the patent application details the dimensions and composition of the AM-transwell, highlighting variations in shapes such as cylinders, cubes, and cones, as well as specific height and thickness measurements for optimal functionality. The synthetic bioink used in the manufacturing process includes various components like degradable peptide ink and triacrylate peptide ink, along with specific percentages of HPA, PEGDA, PEGTAC, and other materials. Additionally, methods for making and using the AM-transwell are outlined, including 3D printing techniques and cell-seeding processes for in vitro cell studies. Overall, the patent application presents a novel approach to manufacturing transwells with potential applications in cell culture and research.

To know more about GlobalData’s detailed insights on United Therapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies